Abstract: The aim of the European Council's Resolution CM/res(2016)2 on good reconstitution practices in health care establishments for medicinal products for parenteral use is to guide the health care establishment's decision as to where reconstitution should take place: in the pharmacy or the clinical area. Injectable preparation in hospital pharmacy is performed in Centralised Intra Venous Additive Services (CIVAS). Nevertheless, challenges such as ensuring the sterility of the preparation, the physicochemical stability of the product, and process validation for instance should be taken into account. This opinion paper examines the challenges, impacts, and responsibilities for pharmacists, nurses, and hospital management related to implementing the resolution, regarding the experience of countries where CIVAS are already implemented. It also discusses the opportunities of implementing CIVAS with regard to patient care safety and potential financial savings.
The aim of the European Council's Resolution CM/Res (2016)2 on good reconstitution practices in health care establishments for medicinal products for parenteral use [1] is to guide the health care establishment's decision as to where reconstitution should take place: in the hospital pharmacy or the clinical area, the decision resulting from risks assessment.
Injectable medicine preparation is a high-risk process that may result in errors. Various risks are described: complex preparation, error of drug or diluent, miscalculation, physicochemical stability, sepsis, patient error, error of administration route, and finally knowledge and competence of the staff [2, 3] . Especially in paediatric and neonatal care units, the use of unlicensed or off-label medicines leads to performing multiple dilutions or perfusing inadequate volumes. For this population of patients, De Giorgi et al. performed a Failure Mode, Effects and Criticality Analysis (FMECA) of the entire medication process of injectable medicinal products, paying particular attention to preparation and administration, and demonstrated that the most common failure modes for preparation in wards were microbial contamination, dosage errors, dilution errors, labelling errors, and selection errors [4] .
Among the items addressed in the resolution to secure parenteral medicines reconstitution is preparation in hospital pharmacy for medicinal products with higher residual risk. In that context, the present article focuses on reconstitution of injectable medicinal products in hospital pharmacy that are performed as part of Centralised Intra Venous Additive Services (CIVAS). Ready-to-use parenteral medicinal products are prepared in advance in adequately cleanrooms under the responsibility of the pharmacist. Most of the time, series of standardised doses are prepared (i. e. dose-banding), but doses of medicinal products adapted to a particular patient are also compounded [2] . In the present paper, chemotherapy and Parenteral Nutrition (PN) medicinal products have been excluded from CIVAS, given that their preparation in hospital pharmacy is mandatory, in France for instance [5, 6] .
CIVAS development is heterogeneous among different countries. In Europe, CIVAS were implemented at the initiative of Bonnabry's team in Switzerland and Hecq's team in Belgium, for example. In the United Kingdom (UK), the Breckenridge report from 1976 recognised that aseptic preparation of injectable medicines should be performed in specialist pharmacy facilities [7] . It is to be pointed out the great UK experience of CIVAS, relayed by the Pharmaceutical Aseptic Service Group of the National Health Service (NHS). Long before the European resolution, the CIVAS Handbook [8] was written with the 3 main objectives to assist in the decision making process on establishing a CIVAS, discuss preparation stability and give drug monographs. On the other side of the Atlantic, hospital pharmacies in the United States and Canada usually prepare injectable medicines. Contrarily, in some countries CIVAS are developed to a very limited extent, as it is the case in France.
In this context, the European Council's resolution is designed to harmonise practices throughout Europe. Implementing such a resolution creates challenges for pharmacists, nurses, hospital management, and even authorities. The aim of the present paper is to discuss the challenges and opportunities related to CIVAS regarding the experience of countries where CIVAS are already implemented. It also discusses the advantages of implementing CIVAS with regard to patient care safety and potential financial savings.
Broadly speaking, aseptic reconstitution requires cleanrooms, specific and dedicated equipment, qualified staff and/or robots, adapted and secure software, and an efficient quality-control system to ensure the highest quality of the final product [9] , secure the preparation, and act in accordance with the Pharmaceutical Inspection Co-operation Scheme (PICS). It is important to invest in aseptic reconstitution, and pharmacists has an important part of responsibility to assume [10] .
The main challenge is to ensure microbial and physicochemical stability of the final product. Consequently, one of the biggest risks when preparing injectable medicines is microbial contamination, especially when they are prepared in advance. Impeccable control of the process and early detection of deviations are prerequisites, especially since most injectable marketed medicines contain no preservatives and are designed for extemporaneous administration. A recently published study evaluates the ability of current human and environmental pathogens to grow in parenteral products aseptically prepared in hospital pharmacies. In the study, microbial growth of S. aureus, P. aeruginosa, E. faecium and C. albicans was observed in more than three quarters of tested solutions. The absence or inhibition of growth is attributed to (i) low pH or high osmolarity, which are not expected properties of an injectable solution, or (ii) the medicine's antibiotic/antifungal properties [11] .
Most of the time, when a batch is to be released by the qualified person, results of microbial tests are not available, given that the recommended method to detect microbial contamination described in the European Pharmacopoeia Monograph 2.6.1 [12] requires 14 days incubation in a selected medium and under controlled temperature. In fact, the lack of physicochemical stability of many medicinal products often leads to early release of the prepared batch. Thus, in the meantime, in absence of the completed sterility test, the pharmacist proceeds to the parametric release of the production, after verifying process validation quality parameters such as media fill tests, and staff qualifications and also in-process parameters such as conformity of the environment (particles in air and surface contamination) and microbiological tests on gloves and surfaces. An alternative solution of this parametric release could be to implement rapid sterility tests. For instance, the ScanRDI ® system labels all viable cells by making them fluorescent and detectable by laser on a filtration membrane. A quantitative result on microbiological contamination is provided within 3 hours. The technique was shown to be numerically superior and statistically non-inferior to the compendial European Pharmacopoeia sterility tests [13] . In order to securise the release process, we believe that there is an immediate need to assess these rapid microbial tests by the European Pharmacopoeia. An obvious example is the use of bevacizumab in age-related macular degeneration, recently authorised by the French National Agency for Medicines and Health Product Safety (ANSM). The solution has physicochemical stability for 30 days from the moment it is compounded in a syringe. Given that Pharmacopoeia requires 14 days for microbiological tests, the medicine can only be used for 16 days. This might result in product wastage and difficult management of the inventory in the case of final sterility test instead of parametric release, which may not be as strong evidence of sterile quality if used alone. Contrary to chemotherapy and NP, which are mainly prepared and administered within a short delay, CIVAS poses the challenge of ensuring sterility of the product during the entire storage period. The impermeability of the final packaging to external contamination must be controlled prior to the production step. The British NHS offers an interesting approach: syringe immersion in different microbial medium [14] to test packaging resistance to external contamination. This should be explored more in depth as part of CIVAS implementation.
The second crucial point that pharmacists should consider is the physicochemical stability of the product. While CIVAS minimise the choice of the incorrect diluents thanks to standardised protocols, they introduce the risk of unsatisfactory physicochemical stability of the stored medicine. Data provided by the pharmaceutical industry are most often limited and offer stability of a few hours or a few days at most. Publications that report studies on medicine stability are listed in Stabilis ® , an invaluable database for hospital pharmacists, and in the Handbook on Injectable drugs [15] . Nevertheless, there is a need for more transparency and for pharmaceutical industries to share their stability data. Moreover, hospital pharmacists are obliged to perform stability studies themselves. Factors likely to affect drug stability (e. g. pH, osmolarity, light, temperature, humidity or interaction between content and container) must be carefully checked. Stability studies must be conducted in accordance with International Conference Harmonisation (ICH) guidelines [16] . A european guideline has also been proposed by the GERPAC and the Clinical Pharmacy groups [17] . It is also worth to read the reflection paper on the stability of chemotherapies, which can be in some part extended to CIVAS [18] updated on 2014 [19] . When products are not stable under normal conditions, an alternative approach is the microwave freeze-thaw technique (MFTT), as proposed by the Belgian team of Hecq [20] . A review included 59 studies on MFTT, overall showing an enhanced stability of the stored medicinal products. Similar studies must be conducted and published to benefit the community. Efficient analytical equipment (HPLC, MS-HPLC) is mandatory, and pooling equipment in a few specialised hospitals could be a way to reduce costs. Due to the wide variety of medicines that can be involved in CIVAS, cross contamination in cleanrooms and safety hoods should be checked by dose markers to ensure the quality of the final product. Today, dose markers are mainly developed for chemotherapy preparation units, but could be applied to the preparation of non-toxic medicines.
Implementing CIVAS creates the need for staff recruitment, training, and accreditation. Apart from cost, which will be discussed below, recruiting pharmacy technicians is a challenge due to misunderstandings about the profession and a shortage of graduates. Regarding training and accreditation, it may be helpful to outline an approach for staff accreditation in parenteral nutrition production, for instance [21] . It has been shown that trained pharmaceutical staff require less preparation time as compared to nurses. Indeed, a publication compared the time for producing a cefepime syringe. The results were 3:48 minutes for pharmaceutical technicians as compared to 5:51 minutes for nurses [2] . A challenge observed mainly in chemotherapy reconstitution units is musculoskeletal disorders. This is a real problem encountered by many hospitals. A complementary strategy is the use of robots or filling pumps for repetitive tasks. The difficulty is that required investment cost, amounting to hundreds of thousands of euros, is only partially offset by staff bluntly and the savings in time.
For nurses, the downside of resolution application and CIVAS is that they would prepare fewer injectable medicines and therefore risk losing skills. To avoid this, protocols should be written, mainly for complex calculations and dilutions, as suggested in the European Council Resolution. Nurses' knowledge and ability to prepare injectable medicines should be controlled frequently, and particular attention should be paid to recently trained nurses. On the other hand, nurses would gain time to refocus on patient care. Nevertheless, it should be kept in mind that preparing injectable medicines in hospital pharmacies in advance does not reduce administration-related risks (error of patient, error of administration route, risk of microbial contamination, etc.). Granting nurses additional time probably means reducing such risks, however this must be evidenced by studies.
With regard to the costs of implementing CIVAS, the European Council Resolution suggests that hospitals should develop a new service, i. e. reconstitution in hospital pharmacy, and confers on hospital management the responsibility to implement this. To the author's knowledge, no resources are attributed to hospital managements for this purpose. Apart from the need for a pharmacy (i. e. cleanrooms, equipment such as hoods and/or isolators, qualified staff and/or robots, adapted and secure software), costs involve software management by the IT department, transport between pharmacy and clinical services in the case of residential hospitals, and potential storage services (storage temperature conditions).
Expenses could be partially offset by the choice of medicines to be compounded in CIVAS: a possible strategy is compounding costly products for paediatric patients, for instance. For example, Briot et al. demonstrated that centralised preparation of Mycamine ® in pharmacy generates 80,000.00 euros of product-related savings per year [22] . Funding initiatives for such costly products, for instance by Regional Health Agencies in France, do not encourage CIVAS because most costly products are refunded as part of hospital activity-based payment. Due to recent changes, Regional Agencies will encourage hospitals to limit such expenses. Furthermore, the strategy of costly products is not listed in the grid proposed by the resolution. This grid is designed to guide the choice. Following this,different strategies listed in Table 1 are proposed: protecting staff against toxic medicinal products (ganciclovir), ensuring proper preparation (appropriate diluent, right dilution, etc.), improvement of patient care, the availability of ready-to-use products for emergency medicine (Geneva University Hospital Strategy), and drug wastage reduction (mainly for paediatrics).
To conclude, one of the aims of the resolution is to achieve greater unity between the different countries.
According to literature publications and congress presentations [2, 25] , the feedback of countries where CIVAS are already implemented is overall positive. Nevertheless, Chris Watts from Guys and St Thomas' NHS Foundation Trust relate that aseptic services within the NHS are in serious decline because of hospitals financial problems, difficulties in staff recruitment and changes of legislation [26] . In Swizerland, Bonnabry speaks of "evolution pressure" because of complexification of legal environment, increase of production costs, decrease of acquisition cost, rationalisation and the necessity of a added-value [27] In other countries, and as in the case of other sterile production processes, CIVAS remain difficult to implement particularly because of the complexity of the process and control-related risks. The development of CIVAS is not only a challenge for pharmacists, but for the community as a whole. Naturally, hospital pharmacists remain responsible for the process on account of their expertise and knowledge in the field of medicine compounding. The pharmaceutical industry is advised to provide data related to drug stability and to perform studies to obtain stability-related data. We believe that national and European agencies should (i) clarify related regulations and the status of this activity, and (ii) propose adapted tests to secure and improve the service (e. g. rapid microbial tests). National and regional authorities and hospital management should provide financial support for this service to help with purchasing equipment (clean rooms, hoods or isolators, production software) and staff remuneration. Yet, in the financial strain context burden on hospitals, one can wonder how European countries where CIVAS are not developed will follow the Resolution recommendations. We believe that the implement of CIVAS will not happen in the Resolution sense, but with an objective of profitability. Being cost-effective is difficult to obtain because of all heavy investments previously described. Another approach consists of valorizing the safety provided by injectable medicine compounded in CIVAS as compared to clinical areas. More and more articles dealing with incorrect aseptic techniques in medicine preparation are being published [28] and further positive results could encourage hospital management to invest in developing CIVAS. What is the cost of a dilution error that leads to a patient's death? Or of an infected injectable preparation resulting in complications and additional costs for patient care? They can strongly affect an hospital's reputation. This is not easily quantifiable. Indeed, methods for calculating the cost of medication errors are heterogeneous and require harmonisation [29] . There are no pharmaco-economic studies to assess the impact of CIVAS, however in our view, it is our responsibility at hospital level to perform such studies. These results should aim at raising awareness amongst public authorities in European countries where CIVAS are not implemented.
Another question arises: all hospitals are not suitably sized for CIVAS. Subcontracting between hospitals could be an answer, but this would mean two-tier health care, which would undermine equal access to health services.
